Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.80 |
| ▸ | HRH1 | P35367 | 4/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.80 |
| ▸ | USP2 | O75604 | 3/20 | 0.80 |
| ▸ | HRH2 | P25021 | 2/20 | 0.80 |
| ▸ | HTR2A | P28223 | 2/20 | 0.80 |
| ▸ | HTR2B | P41595 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.80 |
| ▸ | TEK | Q02763 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 5/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.69 |
| ▸ | DRD4 | P21917 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667455 | 0.93 | HRH1 (0.67) | DRD3HRH1KCNH2USP2HRH2 | |
| SCHEMBL12288130 | 0.89 | DRD3 (0.77) | DRD3HRH1KCNH2USP2HRH2 | |
| SCHEMBL12288127 | 0.89 | DRD3 (0.77) | DRD3HRH1KCNH2USP2HRH2 | |
| SCHEMBL10063666 | 0.89 | DRD3 (0.83) | DRD3HRH1KCNH2USP2HRH2 | |
| SCHEMBL13949317 | 0.89 | DRD3 (0.83) | DRD3HRH1KCNH2USP2HRH2 | |
| SCHEMBL13035055 | 0.89 | DRD3 (0.83) | DRD3HRH1KCNH2USP2HRH2 | |
| Levocetirizine SCHEMBL5935097 | 0.89 | DRD3 (1.00) | DRD3HRH1KCNH2USP2HRH2 | |
| Cetirizine SCHEMBL2455487 | 0.89 | DRD3 (1.00) | DRD3HRH1KCNH2USP2HRH2 | |
| Cetirizine SCHEMBL13724610 | 0.89 | DRD3 (1.00) | DRD3HRH1KCNH2USP2HRH2 | |
| Levocetirizine SCHEMBL4914 | 0.89 | DRD3 (1.00) | DRD3HRH1KCNH2USP2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| EP-0955295-B1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB SA (BE) | 2004-05-19 | — | — | EP | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| US-20070142400-A1 | For treatment of allergies; antihistamines | COSSEMENT ERIC | 2007-06-21 | — | — | US | disclosed |
| EP-1718627-A4 | PROCESS FOR PREPARING OPTICALLY ACTIVE CETIRIZINE OR ITS SALT | HANLIM PHARMACEUTICAL CO LTD (KR) | 2007-04-18 | — | — | EP | disclosed |
| US-20060252934-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine | COSSEMENT ERIC | 2006-11-09 | — | — | US | disclosed |
| EP-1718627-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE CETIRIZINE OR ITS SALT | Hanlim Pharmaceutical Co., Ltd. (KR) | 2006-11-08 | — | — | EP | disclosed |
| US-20060229319-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl)-4-[(4-methylphenyl)sulfonyl] piperazine | COSSEMENT ERIC | 2006-10-12 | — | — | US | disclosed |
| US-20060229320-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | GOBERT JEAN | 2006-10-12 | — | — | US | disclosed |
| US-20050182070-A1 | Method for the treatment of allergic conditions | GOBERT JEAN (BE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182069-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2005-08-18 | — | — | US | disclosed |
| US-20030105113-A1 | Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine | COSSEMENT ERIC (BE) | 2003-06-05 | — | — | US | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-6436942-B1 | ADMINISTERING THE ANTIHISTAMINE, CETIRIZINE, PRODUCED FROM THIS INTERMEDIATE OF HIGH OPTICAL PURITY | UCB, S.A. (BE) | 2002-08-20 | — | — | US | disclosed |
| US-6255487-B1 | PREPARING 2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPER-AZINYL)ETHOXY)ACETIC ACID VIA REACTING SUBSTITUTED (2-((1-PIPERAZINYL)ETHOXY)METHYL COMPOUND WITH A DIPHENYLMETHYL HALIDE, THEN HYDROLYZING IN ALCOHOLIC MEDIUM WITH ACID/BASE | UCB, S.A. (BE) | 2001-07-03 | — | — | US | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
| US-6140501-A | CHEMICAL INTERMEDIATES | UCB, S.A. (BE) | 2000-10-31 | — | — | US | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | DRD3 482/4885HRH1 135/4885KCNH2 260/4885 |
| US-20050182070-A1 | Method for the treatment of allergic conditions | CMA1, HRH2, HRH4 | DRD3 800/4885HRH1 4/4885KCNH2 898/4885 |
| US-20030105113-A1 | Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine | RPLP1, QDPR, PRLHR | DRD3 448/4885HRH1 135/4885KCNH2 248/4885 |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | DRD3 448/4885HRH1 135/4885KCNH2 248/4885 |
| US-20070142400-A1 | For treatment of allergies; antihistamines | HRH2, HRH1, HRH4 | DRD3 401/4885HRH1 2/4885KCNH2 574/4885 |
| US-20050182069-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | QDPR, COMT, PRLHR | DRD3 426/4885HRH1 236/4885KCNH2 422/4885 |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | DRD3 448/4885HRH1 135/4885KCNH2 248/4885 |
| US-20060229319-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl)-4-[(4-methylphenyl)sulfonyl] piperazine | HRH2, HRH1, HRH4 | DRD3 1828/4885HRH1 2/4885KCNH2 213/4885 |
| US-20060229320-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | HRH2, CMA1, HRH4 | DRD3 704/4885HRH1 4/4885KCNH2 237/4885 |
| US-20060252934-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl]piperazine | QDPR, PRLHR, COMT | DRD3 419/4885HRH1 251/4885KCNH2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.